We serve Chemical Name:Metralindole CAS:54188-38-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Metralindole
CAS.NO:54188-38-4
Synonyms:2,4,5,6-Tetrahydro-9-methoxy-4-methyl-1H-3,4,6a-triazafluoranthene;Metralindol [INN-Spanish];Metralindolum [INN-Latin];1H-3,4,6a-Triazafluoranthene,2,4,5,6-tetrahydro-9-methoxy-4-methyl;9-methoxy-4-methyl-2,4,5,6-tetrahydro-1H-3,4,6a-triaza-fluoranthene;2,3,5,6-Tetrahydro-8-methoxy-3-methyl-1H-3,4,10b-triazafluoranthen
Molecular Formula:C15H17N3O
Molecular Weight:255.31500
HS Code:2909309090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:461.2ºC at 760 mmHg
Density:1.33g/cm3
Index of Refraction:1.695
PSA:29.76000
Exact Mass:255.13700
LogP:1.27150
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3249
Packing Group:III
Contact us for information like 2,4,5,6-Tetrahydro-9-methoxy-4-methyl-1H-3,4,6a-triazafluoranthene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3,5,6-Tetrahydro-8-methoxy-3-methyl-1H-3,4,10b-triazafluoranthen physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-methoxy-4-methyl-2,4,5,6-tetrahydro-1H-3,4,6a-triaza-fluoranthene Use and application,2,3,5,6-Tetrahydro-8-methoxy-3-methyl-1H-3,4,10b-triazafluoranthen technical grade,usp/ep/jp grade.
Related News: ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� Metralindole manufacturer ��Ultimately, this is a public health decision,�� she said, adding that the restrictions were precautionary measures to keep the country virus-free and contain the worldwide outbreak. Metralindole supplier To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. Metralindole vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Metralindole factory ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.��
